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Abstract: Prostate cancer (PC) displays a strong familial link and genetic factors; genes 
regulating inflammation may have a pivotal role in the disease. Epigenetic changes control 
chromosomal integrity, gene functions, and, ultimately, carcinogenesis. The most widely studied 
epigenetic event in PC is aberrant DNA methylation (hypo- and hypermethylation); besides this, 
chromatin remodeling and micro RNA (miRNA) are other studied alterations in PC. These all 
lead to genomic instability and inappropriate gene expression. Causative dysfunction of histone 
modifying enzymes results in generic and locus-specific changes in chromatin remodeling. 
miRNA deregulation also contributes to prostate carcinogenesis, including interference with 
androgen-receptor signaling and apoptosis. These epigenetic alterations have the potential to 
act as biomarkers for PC for screening and diagnosis as well as prognosis and follow-up. The 
variable biological potential for a newly diagnosed PC is one of the biggest challenges. The other 
major clinical problem is in the management of castration-resistant PC. Neuroendocrine (NE) 
differentiation is one of the putative explanations for the development of castration-resistant 
disease. Most advanced and poorly differentiated cancer does not produce prostate-specific 
antigen (PSA) in response to disease progression. Circulating and tissue biomarkers like 
chromogranin A (CgA) thus become important tools. There is the potential to use various genetic 
and epigenetic alterations and NE differentiation as therapeutic targets in the management of 
PC. However, we are still some distance from developing clinically effective tools. Valuable 
insights into the nature of NE differentiation in PC have been gained in the last decades, but 
additional understanding of its pathogenetic mechanisms is needed. This will help in devising 
novel therapeutic strategies to develop targeted therapies. CgA has the potential to become an 
important marker of advanced castration-resistant PC in cases where prostate-specific antigen 
can no longer be relied upon. Aberrant androgen-receptor signaling at various levels provides 
evidence of the importance of this pathway for the development of castration-resistant PC. Many 
epigenetic influences – in particular, the role of changing miRNA expression – provide valuable 
insights. Currently, massive sequencing efforts are underway to define important somatic genetic 
alterations (amplifications, deletions, point mutations, translocations) in PC, and these alterations 
hold great promise as prognostic markers and for predicting response to therapy.
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Introduction
It is estimated that there are nearly 2.8 million men living with a history of prostate 
cancer (PC) in the USA, and that an additional 241,740 cases will be diagnosed in 
2012.1 The median age at diagnosis is 67 years.2 PC affects elderly men and incidence 
increases with age. The percentage probability of developing PC increases with age: 
it is 0.01% for those under 40 years of age, 2.63% for those aged between 40 and 
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59 years, 6.84% for those between 60 and 69, and 12.54% 
for those aged over 70 years. During 2006–2008, there was a 
lifetime risk of 16.48% in the USA.3 Similarly, in Europe, PC 
is the most common solid neoplasm and the most common 
form of cancer in men (202,100 incident cases, 18.1% of all 
incident cases in 2004).4 One of the remarkable features of 
PC is wide variation in incidence across ethnic groups. As an 
example, there is a high prevalence among African-American 
(137 cases/100,000 population) compared with the Asian 
population (,10 cases/100,000 population).5
The mechanisms involved in the development of PC are 
still to be determined; however, it is evident that both genetic 
and epigenetic changes contribute to its development and 
progression. “Epigenetic” refers to alterations of the DNA 
or associated proteins, without disturbing the DNA sequence 
and carrying of information regarding gene expression 
during cell division.6 Altered epigenetic gene regulation 
is involved in the genesis and progression of PC. Aberrant 
epigenetic events include DNA hypo- and hypermethylation, 
chromatin remodeling, altered histone modifications, and 
changes in micro RNA (miRNA) expression. All these events 
have been detected in a range of genes associated with PC 
and produce heritable changes in gene expression without 
altering the DNA coding sequence. The list of aberrantly 
epigenetically regulated genes continues to grow; only a few 
genes have, so far, produced promising results as potential 
tumor biomarkers for early diagnosis and risk stratification. 
Epigenetic alterations have the potential to become valuable 
tools for the management of PC. This is due to reversibility 
of epigenetic aberrations with modulators that demethylate 
DNA and inhibit histone deacetylases, leading to reactivation 
of silenced genes. Pharmacologic compounds that reverse 
their nature can target these alterations.
In this brief review, effort is made to review the current 
evidence to improve understanding of the various genetic 
and epigenetic influences, in particular NE differentiation, 
in the causation and progress of PC.
Neuroendocrine differentiation  
in PC
Neuroendocrine (NE) differentiation in PC represents 
a heterogeneous group of entities. NE in differentiation 
has received increasing attention in recent years due to 
prognostic and therapeutic implications. The NE pattern in 
castration-resistant prostate cancer (CRPC) may prove useful 
in selecting potential responders to target therapies such as 
somatostatin analogues. NE cells are derived from non-NE 
PC cells and secrete factors that can act in a paracrine manner 
to stimulate the survival, growth, motility, and metastatic 
potential of prostatic carcinoma cells. NE-differentiated PC 
either involves focal NE cells in the milieu of adenocarcinoma 
or tumors composed exclusively of NE cells (the rare and 
aggressive small cell carcinoma and carcinoid/carcinoid-like 
tumor). There is lack of consensus as to the independent 
prognostic value of focal NE differentiation in PC; however, 
a significant body of current evidence suggests that it has an 
influence on prognosis related to hormone-resistant tumors. 
There are reports as to its role in the conversion to a hormone-
resistant phenotype.
The various transcription factors responsible in the 
development of NE characteristics through prostatic 
adenocarcinoma cells include signal transducer and activator 
of transcription 3, cAMP response element-binding protein, 
early growth response protein 1, c-Fos, and nuclear factor 
kappa B.7 The different molecular markers of NE cells 
include chromogranin A (CgA), neuron-specific enolase, 
B-cell lymphoma 2, and the androgen receptor.8 The NE 
cells secrete a myriad of neuropeptides, which trigger growth 
and survival responses in androgen-independent PC cells. 
These neuropeptides are bombesin, neurotensin, parathyroid 
hormone-related protein, serotonin, and calcitonin.6 PC cell 
receptors that play a role in these processes include the 
gastrin-releasing peptide receptor, neurotensin receptors, and 
the epidermal growth-factor receptor. Signal-transduction 
molecules activated by these neuropeptides include Src, 
focal adhesion kinase, extracellular signal-regulated kinases, 
and phosphatidylinositol 3-kinases/Akt, with subsequent 
activation of E twenty-six-like transcription factor 1, nuclear 
factor kappa B, and c-Myc transcription factors. A multitude 
of genes are then expressed by PC cells, which are involved 
in proliferation, anti-apoptosis, migration, metastasis, and 
angiogenesis. Targeting of these pathways at multiple 
levels can be exploited to inhibit the process by which NE 
cells contribute to the progression of androgen-independent 
treatment-refractory PC.
Genetic factors in the etiology  
of PC
In view of the strong ethnic predisposition, strong family 
association, and familial clustering, there is a strong 
likelihood that genetic factors play an important role in the 
development of PC. In the last several years, genome-wide 
association studies (GWASs) have identified over 36 germ 
line variants of genes that have shown significant association 
with PC susceptibility. The wide variation in the incidence 
of PC in different ethnic groups supports the genetic etiology 
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of PC.5 Aside from age and ethnicity, a positive family history 
is also a significant risk factor.9
Over 40 PC susceptibility loci explaining approximately 
25% of the familial risk have been identified. The majority of 
GWASs reported to date have been conducted in populations 
of European, African-American,10 and Japanese ancestrys.11 
An up-to-date catalog of published GWASs is available 
at the US National Institutes of Health National Human 
Genome Research Institute website (http://www.genome.
gov/gwastudies/).
The genetic factors have been used to assess risk of PC 
development, risk of advanced disease, and duration of 
response to hormonal therapies. In diagnosis and screening, 
there is significant potential for the use of urine measurements 
of prostate cancer antigen 3 RNA and the transmembrane 
protease like serine 2 v-ets erythroblastosis viruses and E26 
oncogene homolog (avian) (TMPRSS2-ERG) gene fusion. 
Multiple groups12,13 have developed gene-expression signa-
tures from primary prostate tumors correlating with poor 
prognosis, and attempts to improve and standardize these 
signatures as diagnostic tests have been presented. Massive 
sequencing efforts are underway to define important somatic 
genetic alterations (amplifications, deletions, point muta-
tions, translocations) in PC, and these alterations hold great 
promise as prognostic markers and for predicting response 
to therapy.12
Epigenetic factors influencing 
carcinogenesis
“Epigenetic alterations” are heritable changes in gene 
expression that occur without changes in DNA sequence.14 
Epigenetic changes control chromosomal integrity, 
gene functions, and, ultimately, carcinogenesis. The 
aberrant epigenetic events in PC include DNA hypo- and 
hypermethylation, chromatin remodeling, altered histone 
modifications, and changes in miRNA expression. The 
most studied of these is DNA methylation. However, it is 
not completely understood what induces these epigenetic 
alterations in cancer; in addition, their role in prostate 
tumorigenesis is being evaluated. Identification of the 
epigenetic modifications involved in the development and 
progression of PC will aid in identifying novel therapeutic 
targets and indicators of biological and diagnostic markers.
DNA hypo- and hypermethylation
DNA methylation plays an important role in regulating gene 
activity, the DNA repair process, and recombination and replica-
tion. DNA methylation involves the addition of a methyl group 
to the 5′-carbon of cytosine in the phosphodiesterase bond 
between cytosine and guanine (CpG) dinucleotide sequences; 
a family of DNA methyltransferases catalyzes this step.
DNA methylation can regulate gene activity via two 
mechanisms. First, methylation of CpG dinucleotides within 
transcription-factor binding sites can inhibit transcription-
factor binding and, therefore, directly influence gene 
activity.15 Secondly, methylated CpG dinucleotides act as 
binding sites for methyl CpG binding proteins, which are 
associated with other factors such as histone deacetylases, 
involved in establishing repressive chromatin structures.16 
These methylation changes have been implicated in the 
tumorigenesis of PC; however, these changes are complex. 
They involve both hypo- and hypermethylation. Aberrant 
DNA hypermethylation occurs when there is an increase in 
DNA methylation at unmethylated regions. Hypermethylation 
at gene promoters can lead to its inactivation. In contrast, 
“DNA hypomethylation” is the demethylation of normally 
methylated DNA and can lead to chromosomal instability 
and activation of proto-oncogenes.
Chromatin remodeling and histone 
modifications
Chromatin is composed of a protein core, which is made 
up of eight histones, around which 147 bp of DNA is 
wrapped.17 Histones not only provide physical support to 
DNA but also are involved in regulating its transcription, 
repair, and replication.15,16,18 Various posttranslational 
biochemical modifications such as acetylation, methylation, 
and phosphorylation can potentially affect the histone tail.15,19 
This results in the histone code, which involves structural and 
translational changes. These alterations decrease the affinity 
of histones for DNA. Consequently, an “open” chromatin 
conformation results and allows the gene transcription to 
take place. Contrarily, histone deacetylation is associated 
with closed, or repressive, chromatin. Two enzymes involved 
in creating an equilibrium state between acetylation and 
deacetylation are histone acetyltransferases and histone 
deacetylases. Similarly, histone methylation may be associated 
with either transcriptional promotion or repression. The 
histone methylation is modified by two enzymes – histone 
methyltransferases and histone demethylases.15,16,18 In malignant 
cells, genome-wide histone modification is also altered in 
concert with changes in DNA methylation.20 Interestingly, the 
same repressive histone marks were identified in certain genes 
with tumor-suppressor behavior that are not silenced by DNA 
methylation.21 Accordingly, alterations in the expression of key 
histone-modulating enzymes (histone deacetylases, histone 
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acetyltransferases, histone methyltransferases, and histone 
demethylases) have been associated with cancer development 
and progression.13,22,23
miRNA
“Micro RNAs” are endogenous non-coding RNAs that 
can interfere with protein expression either by inducing 
the cleavage of specific target messenger RNAs or, in 
most cases, by inhibiting their translation.24 Review of the 
contemporary literature reveals that though over 48 miRNAs 
have been implicated in PC, only a few have been shown 
to be of clinical significance. The most significant clinical 
impact of miRNA is to provide an alternative mechanism 
sustaining androgen-independent growth.25 It has been 
shown that miRs-221, -222, -23b, -27b, -15a, -16-1, and 
-203 are differentially expressed in the hormone-sensitive 
LNCaP cell line and the hormone-resistant LNCaP-abl cell 
line.26 This suggests that these miRNAs may characterize 
certain subtypes of human CRPC. In a recent work, Sun 
and colleagues suggested that altered miR-221/-222 and 
miR-23b/-27b expression may be associated with the 
CRPC process.27 However, it has also been suggested that 
androgens may play a role in downregulation of miR-
221/-222.23 Other miRNAs are also potential modulators 
of androgen receptor-mediated signaling. Besides altering 
androgen-receptor signaling, miRNAs are also implicated in 
attributing immortality to PC cells through the avoidance of 
apoptosis. This is achieved by overexpression of miR-2128 
and downregulation miR-34a29 and miR-34c.30
Current markers
The biological potential of PC is highly variable. The majority 
of PCs is indolent and is diagnosed in the sixth to eighth 
decades of life. The majority of elderly males is likely to die 
of other causes and not from cancer. Therefore, it is often 
unnecessary to subject them to invasive and potentially 
morbid treatment options. Currently, PSA is the only 
surrogate marker for diagnosis, prognosis, and follow-up of 
patients with PC. It is an excellent marker in the follow-up of 
PC patients managed medically or surgically. However, there 
are significant issues with PSA’s diagnostic, screening,31 and 
predictive/prognostic value.32
Potential new markers
There is an urgent clinical need for the identification of 
novel biomarkers in PC. Current development in the field 
of proteomic techniques holds the promise of providing 
new tools with which to find novel PC biomarkers for early 
diagnosis and prognosis.
CgA is an acidic glycoprotein that is commonly 
expressed by NE cells and constitutes one of the most 
profuse components of secretory granules. Its concentration 
is thought to be elevated in relation to NE differentiation of 
PC. Most advanced PC becomes anaplastic and does not 
express PSA in tissue or produce PSA in congruence with 
the increasing bulk of the cancer. In such a situation, PSA 
becomes an unreliable marker of disease progression. Thus, 
CgA is a useful predictive marker in patients with prostatic 
cancer who have a lower PSA level.
CgA and PSA are complementary tumor markers 
in CRPC.33 CgA may help in predicting the response to 
docetaxel therapy. Rising CgA levels during therapy may 
be associated with poor prognosis whereas CgA response is 
likely to be associated with clinical response.
It is known that NE cells in the prostate do not contain 
androgen receptors and are not regulated by androgens. 
PSA expression can be stimulated by androgen through 
androgen receptors, so it is suggested that cases of PC 
associated with low serum PSA and high serum CgA, 
which would have more NE cells with less androgen 
receptors, may show resistance to endocrine therapy and a 
poor prognosis. Therefore, serum CgA tends to be elevated 
in high-grade PC cases. Hence, it can be used to fill any 
gap left by PSA and, when combined with serum PSA, 
the serum marker may effectively predict prognosis after 
endocrine therapy. CgA expression in PC biopsies is an 
independent extrapolative factor of hormone-refractory 
disease in patients with newly diagnosed PC on early 
androgen-deprivation therapy.
Genetic markers
The use of genetic markers has the potential to aid disease 
screening and to improve prognostic discrimination and 
prediction of response to treatment. However, most markers 
have not been prospectively validated for providing useful 
prognostic or predictive information or improvement upon 
clinicopathologic parameters already in use. Significant 
efforts are underway to develop these research findings into 
clinically useful diagnostic tests in order to improve clinical 
decision-making.
Epigenetic biomarkers
Among the promising serum epigenetic markers in PC 
for cancer detection due to DNA methylation are GSTP1, 
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PTGS2, RPRM, TIG1, and one related to miRNA – miR-141. 
The tissue markers related to DNA methylation include 
GSTP1, APC, PTGS2, and MDR1. Among the various 
tissue markers used in the prognosis and prediction of the 
biological potential of the tumor are APC, CD44, PITX2, and 
PTGS2; H3K4me, H3K4me2, H3K18Ac, EZH2, and LSD1 
(DNA methylation); and miRs-34c, -96, -135b, and -194 
(miRNA).34
Conclusion
In the last few decades, valuable insights have been gained 
regarding the nature of NE differentiation in PC in the 
last decades; further understanding of its pathogenetic 
mechanisms is still required. Understanding of the 
development and progression of PC, and the factors that 
drive the development of androgen independence, are better 
understood in light of NE differentiation. The fact that most 
cancers eventually produce androgen-independent clones 
highlights the variety of genetic changes in the primary 
tumor that result in phenotypically distinct cells with different 
cellular capabilities, and their own characteristic response to 
the dynamic microenvironment. This will help in devising 
novel therapeutic strategies to develop targeted therapies. 
CgA has the potential to become an important marker of 
advanced CRPC when PSA can no longer be relied upon. 
Aberrant androgen-receptor signaling at various levels 
provides evidence of the importance of this pathway for 
the development of CRPC. Many epigenetic influences – in 
particular, the role of changing miRNA expression – provide 
valuable insights. Massive sequencing efforts are underway to 
define important somatic genetic alterations (amplifications, 
deletions, point mutations, translocations) in PC, and these 
alterations hold great promise as prognostic markers and for 
predicting response to therapy.
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